Basic Information
| RNALocate ID: | RLID:11001770 |
| RNA Symbol: | hsa-miR-141-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-141 |
| RNA ID: | miRBase:MIMAT0000432 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20976003 |
| Tissue/Cell Line: | Breast cancer cell line (MCF-7) |
| Method: | Microarray |
| Description: | Because of the suggested roles of extracellular miRNAs in signaling and diagnosis, we investigated whether the intracellular and extracellular miRNA composition are the same. To answer this question, we performed microRNA microarray analyses of MCF7 cellular (c) and extracellular (x) RNAs (Figure 2A), and found that about 66% of the released miRNAs are at an abundance that closely reflects the cellular miRNA abundance (Figures 2B and 2C). This finding is in agreement with a model wherein most, but not all miRNAs are released passively by mass action. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001783 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:01001784 | P-body | HeLa cells | 28488892 |
| RLID:11001768 | Exosome | Human milk | 28688106 |
| RLID:11001769 | Exosome | Pulmonary epithelial cell line (BEAS-2B) | 31520698 |
| RLID:11001771 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11001772 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001773 | Exosome | Brain tissue | 23382797 |
| RLID:11001774 | Exosome | Plasma | 23663360 |
| RLID:11001775 | Microvesicle | Seminal plasma | 23539611 |
| RLID:21000268 | Cytoplasmic stress granule | HeLa cells | 28488892 |
| RLID-D:11000082 | Exosome | Breast milk|Colon tissue|Seminal fluid | |
| RLID-D:11000360 | Microvesicle | Colon cancer cell line (LIM1863)|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-141-3p | Splenic marginal zone lymphoma | MNDR-E-MI-13652 |
| MNDR | hsa-miR-141-3p | Renal fibrosis | MNDR-E-MI-13653 |
| MNDR | hsa-miR-141-3p | Oral squamous cell carcinoma | MNDR-E-MI-13654 |
| MNDR | hsa-miR-141-3p | Large cell neuroendocrine cancer | MNDR-E-MI-13655 |
| MNDR | hsa-miR-141-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-13656 |
| MNDR | hsa-miR-141-3p | Ovarian clear cell carcinoma | MNDR-E-MI-13657 |
| MNDR | hsa-miR-141-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-13658 |
| MNDR | hsa-miR-141-3p | Lymphoma | MNDR-E-MI-13659 |
| MNDR | hsa-miR-141-3p | Lymphoma non-hodgkin | MNDR-E-MI-13660 |
| MNDR | hsa-miR-141-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-13661 |
| MNDR | hsa-miR-141-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-13662 |
| MNDR | hsa-miR-141-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-13663 |
| MNDR | hsa-miR-141-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-13664 |
| MNDR | hsa-miR-141-3p | Her2-receptor positive breast cancer | MNDR-E-MI-13665 |
| MNDR | hsa-miR-141-3p | Breast cancer luminal | MNDR-E-MI-13666 |
| MNDR | hsa-miR-141-3p | Dermatomyositis | MNDR-E-MI-13667 |
| MNDR | hsa-miR-141-3p | Prostate cancer | MNDR-E-MI-13668 |
| MNDR | hsa-miR-141-3p | Gastric cancer | MNDR-E-MI-13669 |
| MNDR | hsa-miR-141-3p | Gastric lymphoma | MNDR-E-MI-13670 |
| MNDR | hsa-miR-141-3p | Alzheimer disease | MNDR-E-MI-13671 |
| MNDR | hsa-miR-141-3p | Sickle cell anemia | MNDR-E-MI-13672 |
| MNDR | hsa-miR-141-3p | Bladder cancer | MNDR-E-MI-13673 |
| MNDR | hsa-miR-141-3p | Esophageal carcinoma | MNDR-E-MI-13674 |
| MNDR | hsa-miR-141-3p | Dysautonomia familial | MNDR-E-MI-13675 |
| MNDR | hsa-miR-141-3p | Head and neck cancer | MNDR-E-MI-13676 |
| MNDR | hsa-miR-141-3p | Huntington disease | MNDR-E-MI-13677 |
| MNDR | hsa-miR-141-3p | Chorea | MNDR-E-MI-13678 |
| MNDR | hsa-miR-141-3p | Cardiovascular disease | MNDR-E-MI-13679 |
| MNDR | hsa-miR-141-3p | Lung cancer | MNDR-E-MI-13680 |
| MNDR | hsa-miR-141-3p | Endometrial cancer | MNDR-E-MI-13681 |
| MNDR | hsa-miR-141-3p | Parkinson disease | MNDR-E-MI-13682 |
| MNDR | hsa-miR-141-3p | Breast cancer | MNDR-E-MI-13683 |
| MNDR | hsa-miR-141-3p | Cancer | MNDR-E-MI-13684 |
| MNDR | hsa-miR-141-3p | Thyroid cancer | MNDR-E-MI-13685 |
| MNDR | hsa-miR-141-3p | Pituitary neoplasms | MNDR-E-MI-13686 |
| MNDR | hsa-miR-141-3p | Pancreatic cancer | MNDR-E-MI-13687 |
| MNDR | hsa-miR-141-3p | Melanoma | MNDR-E-MI-13688 |
| MNDR | hsa-miR-141-3p | Rectum adenocarcinoma | MNDR-E-MI-13689 |
| MNDR | hsa-miR-141-3p | Nephroblastoma | MNDR-E-MI-13690 |
| MNDR | hsa-miR-141-3p | Colon cancer | MNDR-E-MI-13691 |
| MNDR | hsa-miR-141-3p | Ischemic attack transient | MNDR-E-MI-13692 |
| MNDR | hsa-miR-141-3p | Colon adenocarcinoma | MNDR-E-MI-13693 |
| MNDR | hsa-miR-141-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-13694 |
| MNDR | hsa-miR-141-3p | Familial ovarian cancer | MNDR-E-MI-13695 |
| MNDR | hsa-miR-141-3p | Prostate adenocarcinoma | MNDR-E-MI-13696 |
| MNDR | hsa-miR-141-3p | Kidney neoplasms | MNDR-E-MI-13697 |
| MNDR | hsa-miR-141-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-13698 |
| MNDR | hsa-miR-141-3p | Carcinoma ductal breast | MNDR-E-MI-13699 |
| MNDR | hsa-miR-141-3p | Glioblastoma | MNDR-E-MI-13700 |
| MNDR | hsa-miR-141-3p | Glioma | MNDR-E-MI-13701 |
| MNDR | hsa-miR-141-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-13702 |
| MNDR | hsa-miR-141-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-13703 |
| MNDR | hsa-miR-141-3p | Epilepsy temporal lobe | MNDR-E-MI-13704 |
| MNDR | hsa-miR-141-3p | Osteosarcoma | MNDR-E-MI-13705 |
| MNDR | hsa-miR-141-3p | Liposarcoma | MNDR-E-MI-13706 |
| MNDR | hsa-miR-141-3p | Breast carcinoma | MNDR-E-MI-13707 |
| MNDR | hsa-miR-141-3p | Liver neoplasms | MNDR-E-MI-13708 |
| MNDR | hsa-miR-141-3p | Choriocarcinoma | MNDR-E-MI-13709 |
| MNDR | hsa-miR-141-3p | Uterine cancer | MNDR-E-MI-13710 |
| MNDR | hsa-miR-141-3p | Cervical adenocarcinoma | MNDR-E-MI-13711 |
| MNDR | hsa-miR-141-3p | Gastric adenocarcinoma | MNDR-E-MI-13712 |
| MNDR | hsa-miR-141-3p | Cervical squamous cell carcinoma | MNDR-E-MI-13713 |
| MNDR | hsa-miR-141-3p | Pituitary adenoma | MNDR-E-MI-13714 |
| MNDR | hsa-miR-141-3p | Lung squamous cell carcinoma | MNDR-E-MI-13715 |
| MNDR | hsa-miR-141-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-13716 |
| MNDR | hsa-miR-141-3p | Lung adenocarcinoma | MNDR-E-MI-13717 |
| MNDR | hsa-miR-141-3p | Adrenocortical carcinoma | MNDR-E-MI-13718 |
| MNDR | hsa-miR-141-3p | Thyroid carcinoma | MNDR-E-MI-13719 |
| MNDR | hsa-miR-141-3p | Ovarian carcinoma | MNDR-E-MI-13720 |
| MNDR | hsa-miR-141-3p | Bladder urothelial carcinoma | MNDR-E-MI-13721 |
| MNDR | hsa-miR-141-3p | Carcinoma renal cell | MNDR-E-MI-13722 |
| MNDR | hsa-miR-141-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-13723 |
| MNDR | hsa-miR-141-3p | Clear cell renal cell carcinoma | MNDR-E-MI-13724 |
| MNDR | hsa-miR-141-3p | Biliary tract cancer | MNDR-E-MI-13725 |
| MNDR | hsa-miR-141-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-13726 |
| MNDR | hsa-miR-141-3p | Cholangiocarcinoma | MNDR-E-MI-13727 |
| MNDR | hsa-miR-141-3p | Lung small cell carcinoma | MNDR-E-MI-13728 |
| MNDR | hsa-miR-141-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-13729 |
| MNDR | hsa-miR-141-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-13730 |
| MNDR | hsa-miR-141-3p | Breast invasive carcinoma | MNDR-E-MI-13731 |
| MNDR | hsa-miR-141-3p | Hepatocellular carcinoma | MNDR-E-MI-13732 |
| MNDR | hsa-miR-141-3p | Familiar ovarian carcinoma | MNDR-E-MI-13733 |
| MNDR | hsa-miR-141-3p | B-cell lymphoma | MNDR-E-MI-13734 |
| MNDR | hsa-miR-141-3p | Rheumatoid arthritis | MNDR-E-MI-13735 |
| MNDR | hsa-miR-141-3p | Ulcerative colitis | MNDR-E-MI-13736 |
| MNDR | hsa-miR-141-3p | Burkitt lymphoma | MNDR-E-MI-13737 |
| MNDR | hsa-miR-141-3p | Crohn disease | MNDR-E-MI-13738 |
| MNDR | hsa-miR-141-3p | Psoriasis | MNDR-E-MI-13739 |
| MNDR | hsa-miR-141-3p | Skin cutaneous melanoma | MNDR-E-MI-13740 |
| MNDR | hsa-miR-141-3p | Skin melanoma | MNDR-E-MI-13741 |
| MNDR | hsa-miR-141-3p | Acute myelogenous leukemia | MNDR-E-MI-13742 |
| MNDR | hsa-miR-141-3p | Colorectal cancer | MNDR-E-MI-13743 |
| MNDR | hsa-miR-141-3p | Nasopharyngeal carcinoma | MNDR-E-MI-13744 |
| MNDR | hsa-miR-141-3p | Nasopharynx carcinoma | MNDR-E-MI-13745 |
| MNDR | hsa-miR-141-3p | Multiple myeloma | MNDR-E-MI-13746 |
| MNDR | hsa-miR-141-3p | Ovarian epithelial cancer | MNDR-E-MI-13747 |
| MNDR | hsa-miR-141-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-13748 |
| MNDR | hsa-miR-141-3p | Uterine cervical neoplasms | MNDR-E-MI-13749 |
| MNDR | hsa-miR-141-3p | Ependymoma | MNDR-E-MI-13750 |
| MNDR | hsa-miR-141-3p | Nasopharyngeal cancer | MNDR-E-MI-13751 |
| MNDR | hsa-miR-141-3p | Prostatic neoplasms | MNDR-E-MI-13752 |
| MNDR | hsa-miR-141-3p | Epstein-barr virus infections | MNDR-E-MI-13753 |
| MNDR | hsa-miR-141-3p | Brain injury chronic | MNDR-E-MI-13754 |
| MNDR | hsa-miR-141-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-13755 |
| MNDR | hsa-miR-141-3p | Pituitary acth hypersecretion | MNDR-E-MI-13756 |
| MNDR | hsa-miR-141-3p | Breast cancer her3+ negative | MNDR-E-MI-13757 |
| MNDR | hsa-miR-141-3p | Low grade dysplastic nodule | MNDR-E-MI-13758 |
| MNDR | hsa-miR-141-3p | Renal childhood neoplasms | MNDR-E-MI-13759 |
| MNDR | hsa-miR-141-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-13760 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ACVR2B | Homo sapiens | RR00039524 |
TOP